a. Cytoplasm | ||
b. Tissue | ||
c. Neoplasm | ||
d. Oncogene |
a. Size | ||
b. Growth pattern | ||
c. Location of origin | ||
d. Appearance |
a. Invasive | ||
b. Benign | ||
c. Metastatic | ||
d. Apoptotic |
a. Studying yeast cell cultures | ||
b. Conducting experiments using mice | ||
c. Researching basic cell biology | ||
d. All of the above |
a. Describing the chemical structure of DNA | ||
b. Outlining how cancer spreads | ||
c. Identifying mutations that cause cancer | ||
d. Establishing guidelines for cancer therapy |
a. Carcinoma | ||
b. Sarcoma | ||
c. Lymphoma | ||
d. Leukemia |
a. Incurability | ||
b. Loss of growth control | ||
c. Origination in lymph | ||
d. Contagiousness |
a. He explained cancer development with autopsy findings. | ||
b. He correlated cancer progression to microscopy findings. | ||
c. He described the humoral theory. | ||
d. He thought that cancer cells came from lymph. |
a. When new cells are being formed faster than needed | ||
b. When cell death surpasses cell division (growth) | ||
c. When cell division equals cell death | ||
d. When cells no longer divide |
a. It was the first induced in lab animals. | ||
b. It was the first known to be caused by a virus. | ||
c. It developed because of the carcinogen tobacco. | ||
d. It was caused by coal tar. |
a. The theory that cancer is infectious is well established and proven true. | ||
b. The theory that cancer is infectious led cancer patients years ago to be housed in the city near other people including doctors. | ||
c. The theory that cancer is infectious was based on several members of the same household contracting breast cancer. | ||
d. The theory that cancer is infectious explains how cancer cells spread within a person. |
a. He described cancer as curable. | ||
b. He did not believe in cancer. | ||
c. He thought that cancer was incurable. | ||
d. He outlined cancer treatments. |
a. He developed anesthesia. | ||
b. He performed autopsies. | ||
c. He did radical mastectomies. | ||
d. He explained that some tumors can be removed. |
a. Celsus | ||
b. Hunter | ||
c. Hippocrates | ||
d. House |
a. Adenine | ||
b. Guanine | ||
c. Cytosine | ||
d. Thymine |
a. Thymine dimers | ||
b. Frameshift mutations | ||
c. Insertions | ||
d. Chromosome breaks |
a. Mismatch repair | ||
b. Proofreading | ||
c. Recombination | ||
d. Apoptosis |
a. Protein | ||
b. Nucleic acid | ||
c. Carbohydrate | ||
d. Lipid |
a. Nucleic acids | ||
b. Amino acids | ||
c. Monosaccharides | ||
d. Lipids |
a. Five | ||
b. Three | ||
c. Four | ||
d. Two |
a. One | ||
b. Two | ||
c. Three | ||
d. Four |
a. Create thymine dimers | ||
b. Develop base substitutions | ||
c. Have a frameshift mutation | ||
d. Exchange adenine for guanine |
a. Sucrose | ||
b. Deoxyribose | ||
c. Ribose | ||
d. Fructose |
a. To transfer phosphates | ||
b. To remove phosphates | ||
c. To bind to ligands | ||
d. To block receptor binding |
a. mRNA | ||
b. tRNA | ||
c. rRNA | ||
d. sRNA |
a. No further mutations occur. | ||
b. There will be no impact on DNA. | ||
c. DNA mutations will accumulate. | ||
d. Only repair proteins will be impacted. |
a. Cytoplasm | ||
b. Mitochondria | ||
c. Nucleus | ||
d. Cell membrane |
a. Tumor suppressors | ||
b. Oncogenes | ||
c. Proto-oncogenes | ||
d. DNA repair genes |
a. Ligand | ||
b. GTP | ||
c. Adenylyl cyclase | ||
d. cAMP |
a. Differentiation | ||
b. The production of hormones | ||
c. Proliferation of cells | ||
d. Both A and C |
a. Src | ||
b. p53 | ||
c. BRCA-1 | ||
d. Rb |
a. Ligands enter the cell and elicit their effect. | ||
b. The receptor changes conformation and directly causes DNA transcription. | ||
c. The signaling event is amplified inside the cell. | ||
d. Signal transduction cascades run indefinitely. |
a. Beta pleated sheet | ||
b. Double helix | ||
c. Single spiral | ||
d. Hexagonal plane |
a. By transferring a phosphate | ||
b. By removing a methyl group | ||
c. By binding to receptor on cell surface | ||
d. By targeting DNA for transcription |
a. G1 | ||
b. S | ||
c. G2 | ||
d. M |
a. Chromosomes line up in the center of the cell. | ||
b. DNA is replicated. | ||
c. The nuclear membrane disappears. | ||
d. Proteins pull apart the chromosomes. |
a. It is a type of eye cancer. | ||
b. It is a transcription factor. | ||
c. It is a tumor suppressor. | ||
d. All of the above |
a. Oncogenes | ||
b. Tumor suppressors | ||
c. DNA repair genes | ||
d. Accessory proteins |
a. Myc | ||
b. p53 | ||
c. Src | ||
d. Rb |
a. Myc | ||
b. p53 | ||
c. Src | ||
d. Rb |
a. G1/S | ||
b. S/G2 | ||
c. G2/M | ||
d. Metaphase/anaphase transition |
a. Cyclins | ||
b. Cyclin dependent kinases | ||
c. Tumor suppressors | ||
d. Oncogenes |
a. Inactivation of tumor suppressors | ||
b. Mutations of DNA repair genes | ||
c. Conversion of proto-oncogenes to oncogenes | ||
d. All of the above |
a. BRCA1 or BRCA2 testing is used to diagnose breast cancer. | ||
b. BRCA1 or BRCA2 testing screens for an increased risk of developing breast cancer. | ||
c. BRCA1 or BRCA2 testing is easily interpreted. | ||
d. BRCA1 or BRCA2 testing is useful for patients that have breast cancer. |
a. Myc | ||
b. Src | ||
c. p53 | ||
d. Bcl-2 |
a. G1 | ||
b. S | ||
c. G2 | ||
d. M |
a. Hyperplasia | ||
b. Dysplasia | ||
c. Anaplasia | ||
d. Carcinoma in situ |
a. Breast | ||
b. Cervix | ||
c. Liver | ||
d. Lung |
a. Dysplasia | ||
b. Carcinoma in situ | ||
c. Hyperplasia | ||
d. Anaplasia |
a. To develop a polio vaccine | ||
b. To study genetics | ||
c. To conduct numerous scientific studies | ||
d. All of the above |
a. Stimulate death receptor clustering | ||
b. Directly target caspase | ||
c. Block lipid raft fusion | ||
d. Turn off the process of apoptosis |
a. 4 months | ||
b. 3 days | ||
c. 2 weeks | ||
d. 1 hour |
a. It progresses. | ||
b. It is arrested. | ||
c. It takes twice as long. | ||
d. It requires p53. |
a. Ionizing radiation | ||
b. Depletion of growth factors and nutrients needed to survive | ||
c. Infection of the cell by a virus | ||
d. All of the above |
a. Binding of B lymphocytes to death receptors | ||
b. Signals from the mitochondria | ||
c. Granzyme | ||
d. Caspase |
a. p53 | ||
b. Myc | ||
c. IGF | ||
d. Bcl-2 |
a. Caspase | ||
b. p53 | ||
c. Telomerase | ||
d. Ras |
a. It comes before initiation. | ||
b. It does not require initiation. | ||
c. More promoters will lead to a more pronounced risk. | ||
d. Low levels of promoters will not likely cause tumor promotion. |
a. Sarcomas | ||
b. Carcinomas | ||
c. Blastomas | ||
d. All of the above |
a. Telomeres are replaced. | ||
b. Telomeres are removed. | ||
c. Telomeres lengthen. | ||
d. Telomeres shorten. |
a. Necrosis | ||
b. Apoptosis | ||
c. Replication | ||
d. Mutation |
a. Stimulate growth factors. | ||
b. Induce angiogenesis. | ||
c. Build the basement membrane. | ||
d. Destroy extracellular matrix (ECM). |
a. Oncogenesis | ||
b. Metastasis | ||
c. Angiogenesis | ||
d. Anaplasia |
a. Adrenal | ||
b. Lung | ||
c. Liver | ||
d. Renal |
a. Heart | ||
b. Lungs | ||
c. Liver | ||
d. Cervix |
a. Adhesion molecules | ||
b. The absence of growth factors | ||
c. The blood vessel size supplying that tissue | ||
d. Platelets |
a. Breast | ||
b. Lung | ||
c. Blood | ||
d. Colon |
a. VEGF | ||
b. bFGF | ||
c. Endostatin | ||
d. p53 |
a. In the blood | ||
b. In the lymphatic system | ||
c. Through body walls | ||
d. Via the gastrointestinal tract |
a. VEGF | ||
b. p53 | ||
c. Ras | ||
d. BRCA1 |
a. Everyone has slightly different lymphatic networks. | ||
b. More cells are found in lymph than in blood, making it hard to spot cancer cells. | ||
c. Tumor cells do not interact with the lymphatic vessels. | ||
d. Lymph nodes hide cancer cells, making it difficult to detect them there. |
a. Angiogenesis | ||
b. Oncoprogression | ||
c. Hitching | ||
d. Metastasis |
a. An initiator | ||
b. An inducer | ||
c. A promoter | ||
d. Both A and C |
a. Proliferation | ||
b. Biotransformation | ||
c. Promotion | ||
d. Induction |
a. In an animal model | ||
b. In a single concentration | ||
c. In isolation | ||
d. At high rates of speed |
a. Cervical | ||
b. Endometrial | ||
c. Breast | ||
d. Bladder |
a. Genetics | ||
b. Environmental factors | ||
c. Nutritional status | ||
d. Older age |
a. 1 | ||
b. 2A | ||
c. 2B | ||
d. 3 |
a. Time of exposure | ||
b. Potency | ||
c. Dose-response | ||
d. All of the above |
a. Literacy | ||
b. Race | ||
c. Gender | ||
d. Income |
a. UV radiation | ||
b. Oxygen free radicals | ||
c. Genetics | ||
d. Viruses |
a. Smoking | ||
b. Asbestos | ||
c. Radon | ||
d. Arsenic |
a. Aflatoxins | ||
b. Benzene | ||
c. Hepatitis B and C viruses | ||
d. Alcohol |
a. Breast | ||
b. Lung | ||
c. Colorectal | ||
d. Prostate |
a. Breast cancer | ||
b. Colon cancer | ||
c. Cervical cancer | ||
d. Lung cancer |
a. 35 | ||
b. 45 | ||
c. 40 | ||
d. 50 |
a. No later than 21 | ||
b. 30 | ||
c. Before 21 if sexually active | ||
d. Both A and C |
a. Microarray | ||
b. Mammogram | ||
c. Biopsy | ||
d. Oncogram |
a. Metastasis | ||
b. Loss of cell growth | ||
c. Patient's chance of survival | ||
d. Risk for secondary infection |
a. UV radiation | ||
b. Tobacco smoking | ||
c. Radioisotopes | ||
d. Genetics |
a. Sarcoma | ||
b. Blastoma | ||
c. Carcinoma | ||
d. Melanoma |
a. Breast cancer | ||
b. Cervical cancer | ||
c. Prostate cancer | ||
d. Colon cancer |
a. Eat a high fiber diet | ||
b. Exercise daily | ||
c. Avoid tobacco | ||
d. Have an annual check-up |
a. Environmental exposure | ||
b. Genetic predisposition | ||
c. Dietary intake | ||
d. Medical status |
a. Tobacco | ||
b. Poor diet | ||
c. Alcohol | ||
d. Both A and C |
a. Pap | ||
b. Mammogram | ||
c. PSA | ||
d. Fecal occult blood |
a. Pap | ||
b. Mammogram | ||
c. PSA | ||
d. Fecal occult blood |
a. Screening methods provide a definitive diagnosis. | ||
b. Screening methods are used to detect cancer in patients without symptoms. | ||
c. Screening methods should only be used if a patient has cancer symptoms. | ||
d. Screening methods have not made a significant impact on cancer prognosis. |
a. They mark cancer cells to be killed. | ||
b. They block important receptors on cancer cells. | ||
c. They carry toxic substances to the cancer cells. | ||
d. Both A and C |
a. Radiation | ||
b. Immunotherapy | ||
c. Chemotherapy | ||
d. Both A and C |
a. Methotrexate | ||
b. Doxil | ||
c. Mustard gas | ||
d. Avastin |
a. Chronic myelogenous leukemia | ||
b. Lymphoma | ||
c. Kaposi's Sarcoma | ||
d. Acute colon cancer |
a. Cells lining the gastrointestinal track | ||
b. Cancer cells | ||
c. Bone marrow cells | ||
d. Skeletal muscle cells |
a. Inducing apoptosis | ||
b. Cell division | ||
c. Cancer cell proliferation | ||
d. Signaling |
a. Spindle promoter | ||
b. Antimetabolite | ||
c. Genotoxic agent | ||
d. Purine and pyrimidine antagonists |
a. Kinase inhibitor | ||
b. Angiogenesis inhibitor | ||
c. Antimetabolites | ||
d. Antisense oligonucleotides |
a. It is toxic to normal cells. | ||
b. The same siRNA cannot be used a second time if cancer returns. | ||
c. It is impossible to get siRNA into cells. | ||
d. siRNA stimulates an immune response. |
a. Lentivirus | ||
b. Adenovirus | ||
c. Herpes simplex virus | ||
d. Epstein Barr Virus |
a. To repair damaged tissues | ||
b. For long term maintenance | ||
c. To divide into tissue that will form organs | ||
d. To complete body tissues |
a. Esophagus | ||
b. Lung | ||
c. Prostate | ||
d. Colon |